Persistence of the neutralizing antibody response after SARS-CoV-2 infection. (April 2022)

• Record Type: Journal Article
• Authors: Shim, Sang-Mu; Kim, Jun-Won; Jung, Sunhee; Jung, Yujung; Woo, Hye-Min; Yang, Jeong-Sun; Kim, Kyung-Chang; Lee, Joo-Yeon
• Is Part Of: Clinical microbiology and infection. Volume 28:Number 4(2022)
• Page Start: 614.e1
• Page End: 614.e4
• Publication Date: 2022-04
• Subjects: COVID-19 -- ELISA -- Neutralizing antibody -- Plaque-reduction neutralizing test -- SARS-CoV-2; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2021.12.012
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Objective: Neutralizing antibodies are among the factors used to measure an individual's immune status for the control of infectious diseases. We aimed to confirm the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody levels in patients who had recovered from coronavirus disease 2019 (COVID-19). Methods: Plasma donors in South Korea who had completely recovered from SARS-CoV-2 infection had follow-up testing to determine the persistence of neutralizing antibodies using a plaque-reduction neutralization test and ELISA. Results: Of the 111 participants—aged 20–29 years, 37/111 (33.3%); 30–39 years, 17/111 (15.3%); 40–49 years, 23/111 (20.7%); 50–59 years, 21/111 (18.9%); 60–65 years, 13/111 (11.7%); male, 43/111 (38.7%); female, 68/111 (61.3%)—66.1% still had neutralizing antibodies approximately 9 months (range 255–302 days) after confirmation of the diagnosis. Conclusions: In this study we analysed the titre of neutralizing antibodies associated with predicting immune status in individuals with natural infection. Information about the persistence and change in levels of neutralizing antibodies against SARS-CoV-2 can be utilized to provide evidence for developing vaccination schedules for individuals with previous infection.